Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Monitor hyperglycemia and new onset or worsening diabetes mellitus during treatment for all patients.
Monitor ALT,AST, and total bilirubin.